PAR12 ABATACEPT (CTLA4IG) IN COMBINATION WITH METHOTREXATE DEMONSTRATES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OVER TWO YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
May 1, 2005, 00:00
10.1016/S1098-3015(10)62906-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)62906-3/fulltext
Title :
PAR12 ABATACEPT (CTLA4IG) IN COMBINATION WITH METHOTREXATE DEMONSTRATES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OVER TWO YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)62906-3&doi=10.1016/S1098-3015(10)62906-3
First page :
Section Title :
Open access? :
No
Section Order :
343